Volume | 524,927 |
|
|||||
News | - | ||||||
Day High | 38.86 | Low High |
|||||
Day Low | 37.82 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
IDEAYA Biosciences Inc | IDYA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
38.41 | 37.82 | 38.86 | 38.11 | 38.93 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
10,613 | 524,927 | US$ 38.35 | US$ 20,132,708 | - | 20.90 - 47.735 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:20:00 | 94 | US$ 38.11 | USD |
IDEAYA Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.84B | 74.56M | - | 23.39M | -112.96M | -1.52 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
IDEAYA Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IDYA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 39.39 | 40.65 | 36.85 | 38.48 | 774,446 | -1.28 | -3.25% |
1 Month | 40.89 | 42.20 | 35.57 | 38.58 | 1,014,402 | -2.78 | -6.80% |
3 Months | 45.32 | 45.32 | 35.57 | 40.01 | 736,167 | -7.21 | -15.91% |
6 Months | 33.06 | 47.735 | 32.56 | 40.56 | 871,264 | 5.05 | 15.28% |
1 Year | 25.05 | 47.735 | 20.90 | 34.69 | 768,692 | 13.06 | 52.14% |
3 Years | 21.01 | 47.735 | 8.14 | 25.66 | 531,109 | 17.10 | 81.39% |
5 Years | 10.62 | 47.735 | 2.95 | 24.04 | 370,510 | 27.49 | 258.85% |
IDEAYA Biosciences Description
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. |